An advisory committee has recommended that a constipation drug created by Progenics Pharmaceuticals Inc is approved for use in prefilled syringes.
The Committee for Medicinal Products for Human Use – part of the European Medicines Agency – recommended that Relistor gets the green light for use.
The European Commission will consider this when deciding whether the drug – which uses opioid painkillers to treat constipation – is approved for use, while the US Food and Drug Administration (FDA) will also rule on it.
Progenics expects pre-filled syringe commercial launches to take place in the United States and European Union during the second quarter of 2011, pending approval.
Progenics Pharmaceuticals, Inc, of Tarrytown, New York, is a biopharmaceutical firm focusing on the development and commercialisation of innovative therapeutic products to treat the medical needs of patients who have life-threatening diseases and debilitating conditions.
Copyright © Press Association 2010